North America drug delivery devices market is expected to reach USD 699.1 billion by 2024 from USD 490.6 billion in 2016, at a CAGR of 4.5% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
Drug delivery is a process of introducing a therapeutic effect in the human body by administering a pharmaceutical drug at a specific targeted site. Drug delivery system improves the efficacy and safety of drug by controlling the rate, time and release of drug in the body. The drug delivery market is segmented on the basis of route of administration, end users, and region.
On the basis of route of administration the North America drug delivery devices market is segmented into oral, injectable, topical, pulmonary, nasal, ocular, implantable and transmucosal. Oral drug is further segmented based on form into solid drug, semi-solid drug and liquid drug. The solid drugs include and are categorized as tablets, capsules, powders and pills. The semi-solid drugs are further segmented into gels, emulsions and elixirs. The liquid drugs are further classified into solutions and syrups. The Injectable drug delivery segment is further segmented into devices and formulations. The devices segment is categorized as conventional injections, self Injectable devices, Needle free injectors, auto injectors, pen injectors, wearable injectors, other devices. The convention injections sub-segment is further classified by material into glass and plastic injections, by usability disposable and reusable injections and, by type into fillable and pre-filled syringes. The Injectable drug delivery formulations are categorized as conventional drug delivery, novel drug delivery, long acting Injectable. Based on the route of administration, oral drug delivery market dominates the market in 2015 and in the near future injectable drug delivery market will dominate the North America drug delivery devices market with the largest share in the drug delivery market. Topical drug delivery market is considered to be the fastest growing market with the CAGR of 8.3%.
The pulmonary drug delivery segment is further classified into metered dose inhalers (MDI), dry powder inhalers (DPI) and nebulizers. The nebulizers are further sub segmented into jet nebulizers, ultrasonic nebulizers and soft mist nebulizers.
Ocular drug delivery devices are segmented into liquid ocular drugs, semi solid ocular drugs and ocular devices. Liquid ocular drug delivery includes eye drops and liquid sprays. Semi solid ocular drug delivery includes gels and ointments. The ocular device includes drug coated lenses and ocular inserts.
Nasal drug delivery devices are segmented into nasal drops, powders, gels, and sprays. The topical drug delivery segment is segmented based on form into liquid, semi-solid, solid and transdermal. The transdermal topical drug delivery device includes transdermal patches and transdermal gels. The implantable drug delivery devices segment includes active and passive implantable drug delivery devices. The transmucosal drug delivery segment is sub segmented into oral transmucosal and others. The oral transmucosal segment includes products such as buccal and sunlingual drug delivery devices, while the others segment includes rectal transmucosal drug delivery and vaginal transmucosal drug delivery.
On the basis of end users the market is segmented into hospitals, over the counter, ambulatory surgery centers/clinics, home care settings, diagnostic centers, and others. The hospitals segment dominate the North America drug delivery devices market. Home care settings segment is considered to be the fastest growing market with the CAGR of 5.1%.
The major factors contributing to the growth of the North America drug delivery devices market are rising prevalence of chronic diseases, growth of biologics, new product launches, drug innovation, technological advancements, and decrease in the level of pain. On the other hand, factors such as side effects and injuries, infections, safety measures regarding the use of devices used for the administration of drug, patent expiry, product recall and patent cliff hampers the growth of the market.
Based on geography the market is segmented into 3 countries U.S., Canada and Mexico. U.S. is expected to dominate the market due to rising prevalence of chronic diseases, large healthcare expenditure, and paradigm shift towards value based reimbursements. U.S. dominates the market and is expected to account for the largest share of 93.2% in 2016. This market to poised to witness the largest share due to the increasing prevalence of chronic diseases, development of biologics and pharmaceutical drugs and devices, increasing patient compliance and patient safety.
The report also includes company share analysis for the major companies operating in this market by countries. The details of mergers & acquisitions, product launches, expansions, and product life cycle matrix is also a part of this report. Some of the players in the market Bayer AG, Johnson & Johnson Services, Inc., Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc. , Merck & Co., Sanofi, Antares Pharma, and 3M.